Daesung Microbiological Labs. Co. Ltd (036480) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Daesung Microbiological Labs. Co. Ltd stock KRW 2,395, price KRW 5,090, that is 52.9% below the price, quality 62 out of 100. Rating: strongly overvalued. Calculated from audited financials with 20 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 5,090 KRW – 21,665 KRW · fair‑value band 1,084 KRW – 3,400 KRW · the 5,090 KRW price screens above the 2,395 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Daesung Microbiological Labs. Co. in your weekly email
Every Wednesday you see whether Daesung Microbiological Labs. Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals.
Show moreShow less
The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in Uiwang-si, South Korea.
Stock analysis
Daesung Microbiological Labs. Co. Ltd (036480) currently trades at 5,090 KRW, while our model-based Fair Value estimate is 2,395 KRW, 53% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of 6,307 KRW per share, and 4 of the 20 models we run sit above the 5,090 KRW price.
Bear case: the Asset-Based group reads lowest at 704.31 KRW, and 16 of the 20 models stay below the price. Data coverage for this calculation is high.
Scenario range: 1,084 KRW (bear) to 3,400 KRW (bull), the price of 5,090 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Daesung Microbiological Labs. Co. Ltd reported revenue of 26.0B KRW in FY2025 versus 24.0B KRW in FY2021, a compound +2.0%/yr. Reported net income was 598M KRW in FY2025, compounding −8.8%/yr from FY2021.
Key figures
Market cap 19.3B KRW (≈ $14.2M) Micro · P/E ratio 55.3 · P/S ratio 0.77 · EPS (TTM) 92.31 KRW · Dividend yield 1.5% · Net margin 1.4% · Return on equity 1.0% · Return on assets (EBIT) −0.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −53%, 036480 screens richer than that median.
Fair Value models
Bear1,084 KRWFair Value 2,395 KRWBull3,400 KRW
Price 5,090 KRW · Downside -52.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (14.84 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Start year 2020 (pandemic). Over 10 years: −1.8% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−15.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.0%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.0% vs −18.3%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 3%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.3%/yr over ~8Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +11.4% a year for the price.
Compare Daesung Microbiological Labs. Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Top 25%
Fair Value upside−52.9% · Below median
Profitability
Return on equity (12 months)1.0% · Above median
Return on assets1.0% · Above median
Net margin (12 months)1.4% · Below median
Operating margin (12 months)−7.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)−10.1% · Below median
Dividend yield (12 months)1.5% · Above median
Balance sheet
Debt / equity0.38× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)55.3× · Priciest 25%
P/B0.54× · Cheapest 25%
P/S (12 months)0.77× · Cheapest 25%
Price / free cash flow (fiscal year)18.3× · Cheaper than median
EV/EBITDA15.8× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)4· sector 0
HEALTH (low debt)81· sector 97
DIVIDEND (yield)29· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Daesung Microbiological Labs. Co. Ltd (036480) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 2,395 KRW versus a price of 5,090 KRW, about 53% lower (overvalued).
What is the fair value of 036480?
Our model-based fair value for Daesung Microbiological Labs. Co. Ltd is 2,395 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 5,090 KRW.
What is the quality score of 036480?
Daesung Microbiological Labs. Co. Ltd has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daesung Microbiological Labs. Co. Ltd (036480)?
Our model-based price target is the fair value of 2,395 KRW (as of Nov 3, 2026) from 20 valuation models. Cautious scenario 1,084 KRW, optimistic scenario 3,400 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daesung Microbiological Labs. Co. Ltd stock forecast for 2026?
Our models put fair value at 2,395 KRW, about 53% lower versus a price of 5,090 KRW (overvalued). Cautious scenario 1,084 KRW, optimistic scenario 3,400 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daesung Microbiological Labs. Co. Ltd (036480)?
Daesung Microbiological Labs. Co. Ltd reported trailing-twelve-month revenue of about 25.2B KRW (latest available figure, as of Nov 3, 2026).
Does Daesung Microbiological Labs. Co. Ltd pay a dividend?
Daesung Microbiological Labs. Co. Ltd currently shows a dividend yield of 1.47% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Daesung Microbiological Labs. Co. Ltd (036480) and when is the ex-dividend date?
Daesung Microbiological Labs. Co. Ltd pays a dividend of 75.00 KRW per share a year, a dividend yield of 1.5%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2001. The payout ratio is 81.2% of earnings. Free cash flow covers the dividend 3.69 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Daesung Microbiological Labs. Co. Ltd (036480)?
For today's price to be fair in a discounted-cash-flow model, Daesung Microbiological Labs. Co. Ltd would have to grow free cash flow by +13.7 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.9 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 036480 use?
Our models discount Daesung Microbiological Labs. Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.07, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daesung Microbiological Labs. Co. Ltd that is +13.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Daesung Microbiological Labs. Co. Ltd (036480) delivered so far?
Over the past 5 years revenue at Daesung Microbiological Labs. Co. Ltd grew +0.9 % a year. The price currently implies free-cash-flow growth of +13.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daesung Microbiological Labs. Co. Ltd (036480) growing?
The median revenue growth in the sector is +14.3 % a year. That is the yardstick for the growth priced into Daesung Microbiological Labs. Co. Ltd (+13.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daesung Microbiological Labs. Co. Ltd (036480)?
The free-cash-flow yield on the price is 5.44 %: that much free cash flow Daesung Microbiological Labs. Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daesung Microbiological Labs. Co. Ltd (036480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daesung Microbiological Labs. Co. Ltd it is 2,395 KRW per share (as of Nov 3, 2026), against a price of 5,090 KRW. It is the blended result of 20 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Daesung Microbiological Labs. Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 036480 trades above its calculated fair value: price 5,090 KRW, fair value 2,395 KRW, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 036480?
No. The price is what the market pays today (5,090 KRW); the fair value is what the company's own numbers justify (2,395 KRW). For Daesung Microbiological Labs. Co. Ltd the two are 2,695 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daesung Microbiological Labs. Co. Ltd worth?
The market values Daesung Microbiological Labs. Co. Ltd at about 19.3B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 5,090 KRW; our models calculate a fair value of 2,395 KRW per share.
What do the bullish and bearish scenarios say about 036480?
Our models span a range for Daesung Microbiological Labs. Co. Ltd: cautious scenario 1,084 KRW, base 2,395 KRW, optimistic 3,400 KRW per share (as of Nov 3, 2026, price 5,090 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 036480?
Daesung Microbiological Labs. Co. Ltd trades at a price-to-earnings ratio of 55.3 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,395 KRW is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2018 to 2025), reported earnings: 31.8. Other multiples: P/B 0.5, P/S 0.8, EV/EBITDA 15.8.
How solid is the balance sheet of Daesung Microbiological Labs. Co. Ltd (036480)?
Balance-sheet figures for Daesung Microbiological Labs. Co. Ltd (as of Nov 3, 2026): return on equity 1.0%, debt of 0.38 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 036480 from its 52-week high?
Daesung Microbiological Labs. Co. Ltd trades at 5,090 KRW, about 48% below its 52-week high of 9,880 KRW and at the low of 5,090 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,395 KRW is for.
Which stocks are comparable to Daesung Microbiological Labs. Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daesung Microbiological Labs. Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 5,090 KRW, calculated fair value 2,395 KRW (−53%), Quality Score 62/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 036480 calculated?
We run Daesung Microbiological Labs. Co. Ltd through 20 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,395 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Daesung Microbiological Labs. Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daesung Microbiological Labs. Co. Ltd (036480)?
The closing price on Nov 6, 2026 was 5,090 KRW. Our model-based fair value is 2,395 KRW, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daesung Microbiological Labs. Co. Ltd right now?
The price sits above even our optimistic bull case (3,400 KRW). The favourable scenario is already priced in. The model range is unusually wide (1,084 KRW to 3,400 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Daesung Microbiological Labs. Co. Ltd
How large is the market capitalisation of Daesung Microbiological Labs. Co. Ltd (036480)?
The market capitalisation of Daesung Microbiological Labs. Co. Ltd is 19.3B KRW (≈ $14.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daesung Microbiological Labs. Co. Ltd (036480)?
The price-to-sales ratio of Daesung Microbiological Labs. Co. Ltd is 0.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Daesung Microbiological Labs. Co. Ltd (036480)?
Earnings per share at Daesung Microbiological Labs. Co. Ltd are 92.31 KRW (price ÷ EPS = P/E 55.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Daesung Microbiological Labs. Co. Ltd (036480)?
The dividend yield of Daesung Microbiological Labs. Co. Ltd is 1.5% (payout 81.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daesung Microbiological Labs. Co. Ltd (036480)?
The net margin of Daesung Microbiological Labs. Co. Ltd is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daesung Microbiological Labs. Co. Ltd (036480)?
The return on equity (ROE) of Daesung Microbiological Labs. Co. Ltd is 1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daesung Microbiological Labs. Co. Ltd (036480)?
On an EBIT basis the return on assets of Daesung Microbiological Labs. Co. Ltd is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daesung Microbiological Labs. Co. Ltd (036480)?
The operating margin of Daesung Microbiological Labs. Co. Ltd is −7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daesung Microbiological Labs. Co. Ltd (036480)?
Revenue at Daesung Microbiological Labs. Co. Ltd is growing −10.1% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daesung Microbiological Labs. Co. Ltd (036480)?
Earnings per share at Daesung Microbiological Labs. Co. Ltd are growing −75.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Daesung Microbiological Labs. Co. Ltd (036480) carry?
The net debt of Daesung Microbiological Labs. Co. Ltd is 16.2B KRW (fiscal year 2025, ≈ 15.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daesung Microbiological Labs. Co. Ltd in the live analysis
One click puts Daesung Microbiological Labs. Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026